The FDA is forcing a small antibiotic player back to the clinic for a new trial — 10 years after first rejection

Motif Bio got a clear enough answer from the FDA on what regulators will need to see before they reconsider an OK on their antibiotic iclaprim. And it’s not what their dwindling band of investors wanted to hear.